CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.
|Strength||200 mg & 250 mg|
|Indication||ROS1-positive advanced Non-Small Cell Lung Cancer|
|Funding Request||As a single agent as first-line treatment for patients with ROS1-positive advanced non-small cell lung cancer (NSCLC)|
|Pre Noc Submission||No|
|NOC Date||August 28, 2017|
|Manufacturer||Pfizer Canada Inc.|
|Sponsor||Cancer Care Ontario Lung Cancer Drug Advisory Committee|
|Submission Date||October 30, 2018|
|Submission Deemed Complete||November 13, 2018|
|Stakeholder Input Deadline ‡||November 13, 2018|
|Check-point meeting||January 22, 2019|
|pERC Meeting||April 18, 2019|
|Initial Recommendation Issued||May 3, 2019|
|Feedback Deadline ‡||May 17, 2019|
|Final Recommendation Issued||May 23, 2019|
|Notification to Implement Issued||June 7, 2019|
|Therapeutic Area||ROS1-positive advanced non-small cell lung cancer (NSCLC)|
|Recommendation Type||Reimburse with clinical criteria and/or conditions|
‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.